• Explore /
  • Poster
  • / Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune checkpoint inhibitors (CPIs).

Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune checkpoint inhibitors (CPIs).

Abstract Poster

Authors

null

Michael Edward Devitt

University of Virginia, Charlottesville, VA

Michael Edward Devitt , Ralph Sumner Abraham , Jacobi Hines , Bethany J Horton , Camilo E. Fadul , James Mitchell Larner , Jason Sheehan , Richard Delmar Hall , Ryan D. Gentzler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Brain Metastases

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2010)

DOI

10.1200/JCO.2018.36.15_suppl.2010

Abstract #

2010

Poster Bd #

168

Abstract Disclosures

Similar Posters

First Author: Jonathan Wade Goldman

First Author: Taiga KOMATSU

First Author: Ethan Burns

First Author: Suzanne Phillips